Immunologic Changes during Unplanned Treatment Interruptions of Highly Active Antiretroviral Therapy in Children with Human Immunodeficiency Virus Type 1 Infection

Pediatric Infectious Disease Journal

Volumn 23, Issue 5, 2004, Pages 446-450

  Gibb, Diana M ^a,c   Duong, Trinh ^a   Leclezio, Veronica A ^a   Walker, A Sarah ^a   Verweel, Gwenda ^b   Dunn, David T ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

CD4; Children; Highly active antiretroviral therapy; Human immunodeficiency virus; Interruptions

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; IRELAND; NETHERLANDS; RNA, VIRAL; VIRAL LOAD;

EID: 2442599032     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000122601.62358.74     Document Type: Article

References (9)

1. Gibb DM, Duong T, Tookey PA, et al. on behalf of the National Study of HIV in Pregnancy and Childhood (NSHPC) and of the Collaborative HIV Paediatric Study (CHIPS). Decline in mortality, AIDS and hospital admissions in perinatally HIV-1 infected children in the UK and Ireland. BMJ. 2003;327:1019-1023.
2. Wade AM. Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med. 1994;13:2359-2367.
3. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis. 2002;186:312-320.
4. Rasbash J, Woodhouse G. MLn Command Reference. Multilevel Models Project, Institute of Education, University of London, 1995.
5. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43 (RR-12).
6. Youle M, Janossy G, Turnbull W, et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. AIDS. 2000;14:1717-1720.
7. Taffe P, Rickenback M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16:747-755.
8. Garcia F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F29-F40.
9. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS. 2003;17: 126-128.